-
A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors.
You can participate in this study if you are diagnosed with stage 3 or stage 4 skin melanoma. The purpose of this study is to ... -
A Phase 1b First-in-human Dose Escalation and Expansion Multicenter Study of XMT-1660 in Participants with Solid Tumors
If you are diagnosed with stage 4 tumor of any solid origin, for example; breast, endometrial, ovarian, fallopian tube, cervix, vaginal or primary peritoneal cancer ...
-
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to test the safety of ... -
A Phase I Open-label Multi-center Clinical Study to Evaluate Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies
This study is designed for patients diagnosed with metastatic castration resistant prostate cancer (mCRPC).
This is a Phase I, first-in-human, open-label, multi-center dose-escalation study of ...